Thelansis

 Menorrhagia, also recognized as heavy menstrual bleeding, significantly hampers regular activities, impacts quality of life, and induces anemia in approximately two-thirds of women experiencing objective Menorrhagia (defined as a loss of 80 mL blood per cycle). Termed abnormal uterine bleeding for precision, Menorrhagia can be categorized into nine groups under the PALM-COEIN acronym: 1.        Polyp 2.        Adenomyosis 3.        Leiomyoma 4.        Malignancy and hyperplasia 5.        Coagulopathy 6.        Ovulatory dysfunction stemming from conditions like hypothyroidism, hyperthyroidism, prolactin-secreting tumors, or PCOS 7.        Endometrial factors 8.        Iatrogenic causes, such as the use of IUDs, chemotherapeutic a...

 Menorrhagia is a medical term for heavy or prolonged menstrual bleeding or excessive blood loss during a period. ·        The annual Menorrhagia prevalence rate is 53 per 1000 women. Thelansis’s “Menorrhagia Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Menorrhagia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Menorrhagia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. Menorrhagia Market Forec...